Novel Drug Delivery Systems in the Management of Cns Disorders
Language: English
Published by Academic Pr, 2024
- Softcover
- New

Seller: Revaluation Books, Exeter, United KingdomRevaluation Books
AbeBooks seller since January 6, 2003
Condition: New
£ 152.57
Quantity: 2 available
Add to basketItem description from seller
400 pages. 9.21x7.50x2.52 inches. In Stock.
Seller Inventory # __044313474X
- Title
- Novel Drug Delivery Systems in the Management of Cns Disorders
- Author
- Chawla, Pooja A. (Editor)/ Loebenberg, Raimar (Editor)/ Dua, Kamal (Editor)/ Parikh, Vinay (Editor)/ Chawla, Viney (Editor)
- Publisher
- Academic Pr
- Publication year
- 2024
- Condition
- Brand New
- Binding
- Paperback
- Language
- English
- ISBN 10
- 044313474X
- ISBN 13
- 9780443134746
- Item weight
- 1.41 kilograms
Novel Drug Delivery Systems in the Management of CNS Disorders offers a comprehensive source of information on delivering drugs to the central nervous system to treat various diseases and conditions. The book covers a wide range of CNS disorders, including epilepsy, Parkinson's, Alzheimer's, Huntington's, multiple sclerosis, schizophrenia, cerebral palsy, autism, ALS, and others.
The book begins by presenting the foundations of drug delivery to the brain and addressing the associated challenges. It then delves into clinical trials and explores the future potential of the presented technologies.
This reference is designed for drug delivery researchers in academia and corporations, providing them with the essential knowledge about overcoming the Brain-Blood Barrier and achieving targeted drug delivery to the central nervous system.
- Consolidates current state of the art research into a single book volume
- Presents the challenges of drug delivery to the CNS in a comprehensive way
- Covers the most relevant CNS conditions and diseases
- Provides future perspectives and the most active research areas in this fast-moving field
"Synopsis" may belong to another edition of this title.
About the Author
Dr. Pooja A Chawla is working as a Professor, at the University Institute of Pharmaceutical Sciences, Baba Farid University of Health Sciences, Faridkot, Punjab, India. She has 22 years of experience in the research, discovery, and development of biologically active pharmaceuticals. Dr. Chawla holds a PhD degree in Pharmaceutical Sciences with a specialization in Pharmaceutical Chemistry and has published 6 books, 25 book chapters, and more than 150 papers in national/international journals and is serving as a reviewer for international journals of repute. Dr. Pooja is also privileged to serve as guest editor of two reputed journals CNS & Neurological Disorders - Drug Targets IF 2.8 and Current Organic Chemistry IF 2.5) of Bentham Sciences. She has been appointed as Academic editor of PLOS ONE journal IF 3.2 and recently she has been appointed as Assistant editor for Health Sciences Review Journal by Elsevier publishers. She has guided more than 60 postgraduate projects and her research team consists of 6 Masters and 4 Doctoral research scholars. Her area of research interest focuses on the design and synthesis of various heterocyclic moieties including 4-Thiazolidinones, 2,4-Thiazolidiedione, Coumarin, Pyrazolines, Schiff’s base derivatives to name a few for the discovery of medicinally important agents as anticonvulsants, antidepressants, anticancer, anti Alzheimer’s agents. She is well-versed with method development and validation and guiding research scholars in this field.
Dr. Raimar Löbenberg holds a BSc in pharmacy from the Johannes Gutenberg-University in Mainz, Germany and PhD in pharmaceutics from the Johann Wolfgang Goethe-University in Frankfurt. He joined the University of Alberta in 2000. His research interests are in Biopharmaceutics to predict the oral performance of drugs and botanicals and inhalable nanoparticles to treat lung diseases like cancer or tuberculosis. He is founder and director of the Drug Development and Innovation Centre at the University of Alberta. He was president of the Canadian Society for Pharmaceutical Sciences 2014 & 2015. He is member of the United States Pharmacopeia Dietary Supplement Expert Committee. He is Vice Chair of the Specialty Committee of Traditional Chinese Medicine in Pharmaceutics of the World Foundation of Chinese Medicine Science. He is member of the Health Canada Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology.
Dr. Kamal Dua is an Associate Professor in the Discipline of Pharmacy at the Graduate School of Health, University of Technology Sydney (UTS), Australia. He has research experience of over 13 years in the field of drug delivery systems targeting inflammatory diseases. Dr. Dua is also a Node Leader of Drug Delivery Research in the Centre for Inflammation at Centenary Institute/UTS, where the targets identified from the research projects are pursued to develop novel formulations as the first step towards translation into clinics. Dr. Dua research in two complementary areas; drug delivery and immunology, specifically addressing how these disciplines can advance one another, helping the community to live longer and healthier. This is evidenced by his extensive publication record in reputed journals. Dr. Dua’s research interests focus on harnessing the pharmaceutical potential of modulating critical regulators such as Interleukins and microRNAs and developing new and effective drug delivery formulations for the management of chronic airway diseases. He has published more than 100 research articles in peer-reviewed international journals and authored or co-authored four books. He is an active member of many national and international professional societies.
Vinay Parikh is an Associate Professor in the Department of Psychology at Temple University (Philadelphia). He also serves as the Director of Neuroscience Program in Temple’s College of Liberal Arts and provides strategic leadership, direction, and guidance for all educational and professional activities in the program. Dr. Parikh has successfully directed multiple research projects, resulting in notable contributions to the understanding of neural mechanisms underlying cognitive decline in age-related neurodegenerative and psychiatric disorders. His research has also opened new avenues to develop cognition therapies. Dr. Parikh has published more than 90 scientific articles and book chapters in areas of systems and behavioral neuroscience, biological psychiatry, and pharmacology, and serves on several editorial boards of journals. He also regularly serves on scientific advisory and review committees of numerous biomedical research agencies including the National Institute of Health, Alzheimer’s Association, and Michael J Fox Foundation.
Dr. Viney Chawla is working as Professor and Principal at University Institute of Pharmaceutical Sciences and Research, Baba Farid University of Health Sciences, Punjab, India, He has 25 Years of experience in the research, formulation and development of solid lipid nanoparticles, microspheres, nanostructured lipid carriers. Dr. Chawla holds a Ph D Degree in Pharmaceutics and has Published 3 Books, 30 Book Chapters and more than 100 Papers in National/International Journals and is serving as a Reviewer for International Journals of repute. He has guided 40 Post Graduate Projects and his research team consists of 9 Masters and 4 Doctoral Research Scholars.
"About the title" may belong to another edition of this title.
Revaluation Books
Exeter, United Kingdom
AbeBooks seller since January 6, 2003
Shipping rates from United Kingdom to U.S.A.
| Item | 7 to 14 business days | 2 to 3 business days |
|---|---|---|
| First item | £ 15.00 | £ 25.00 |
Payment methods
Seller's business information
Edward Bowditch Ltd
Exstowe, Exton
Exeter, United Kingdom EX3 0PP
Terms of sale
Legal entity name: Edward Bowditch Ltd
Legal entity form: Limited company
Business correspondence address: Exstowe, Exton, Exeter, EX3 0PP
Company registration number: 04916632
VAT registration: GB834241546
Authorised representative: Mr. E. Bowditch
Right of withdrawal
If you are a consumer you can withdraw from the contract in accordance with the following. Consumer means any natural person who is acting for purposes which are outside his trade, business, craft or profession.
Information regarding the right of withdrawal
Statutory right to withdraw
You have the right to withdraw from this contract within 14 days without giving any reason.
The withdrawal period will expire after 14 days from the day on which you acquire, or a third party other than the carrier and indicated by you acquires, physical possession of the last good or the last lot or piece.
To exercise the right of withdrawal, electronically fill in and submit a clear statement on our website, under "My Purchases" in "My Account". We will communicate to you an acknowledgement of receipt of such a withdrawal on a durable medium (e.g. by e-mail) without delay.
To meet the withdrawal deadline, it is sufficient for you to send your communication concerning your exercise of the right of withdrawal before the withdrawal period has expired.
Effects of withdrawal
If you withdraw from this contract, we will reimburse to you all payments received from you, including the costs of delivery (except for the supplementary costs arising if you chose a type of delivery other than the least expensive type of standard delivery offered by us).
We may make a deduction from the reimbursement for loss in value of any goods supplied, if the loss is the result of unnecessary handling by you.
We will make the reimbursement without undue delay, and not later than 14 days after the day on which we are informed about your decision to withdraw from this contract.
We will make the reimbursement using the same means of payment as you used for the initial transaction, unless you have expressly agreed otherwise; in any event, you will not incur any fees as a result of such reimbursement.
We may withhold reimbursement until we have received the goods back, or you have supplied evidence of having sent back the goods, whichever is the earliest.
You shall send back the goods or hand them over to Revaluation Books, Hounslow, United Kingdom, without undue delay and in any event not later than 14 days from the day on which you communicate your withdrawal from this contract to us. The deadline is met if you send back the goods before the period of 14 days has expired. You will have to bear the direct cost of returning the goods. You are only liable for any diminished value of the goods resulting from the handling other than what is necessary to establish the nature, characteristics and functioning of the goods.
Exceptions to the right of withdrawal
The right of withdrawal does not apply to:
- The delivery of newspapers, journals or magazines with the exception of subscription contracts; and
- The supply of digital content which is not supplied on a tangible medium (e.g. on a CD or DVD) if you accepted when you placed your order that we could start to deliver it, and that you could not withdraw once delivery had started.
Shipping terms
Orders usually dispatched within two working days.